CLDI AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
CLDI Current Performance
-7.17%
Calidi biotherapeutics inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to CLDI
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
MNPR | Monopar therapeutics inc | 2 | 3 | 4 | 1 | 1 | |
TBIO | Telesis bio inc | 2 | 3 | 4 | 1 | 1 | |
MRVI | Maravai lifesciences holdings inc | 2 | 4 | 2 | 3 | 1 | |
VTYX | Ventyx biosciences inc | - | 3 | 3 | 3 | 1 | |
OCEA | Ocean biomedical inc | - | 2 | 3 | 1 | 1 |
- MNPR Monopar therapeutics incValue 2Trend 3Swing Trading 4Whale Interest 1Dividend 1See more
CLDI Profile
Calidi Biotherapeutics Inc Formerly kn own as First Light Acquisition Group Inc. Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.